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Abstract
Background: Neuroprotection and promotion of remyelination represent important therapeutic gaps in multiple
sclerosis (MS). Acute optic neuritis (ON) is a frequent MS manifestation. Based on the presence and properties of
sphingosine-1-phosphate receptors (S1PR) on astrocytes and oligodendrocytes, we hypothesized that remyelination
can be enhanced by treatment with fingolimod, a S1PR modulator currently licensed for relapsing-remitting MS.
Methods: MOVING was an investigator-driven, rater-blind, randomized clinical trial. Patients with acute unilateral
ON, occurring as a clinically isolated syndrome or MS relapse, were randomized to 6 months of treatment with 0.5
mg oral fingolimod or subcutaneous IFN-β 1b 250 μg every other day. The change in multifocal visual evoked
potential (mfVEP) latency of the qualifying eye was examined as the primary (month 6 vs. baseline) and secondary
(months 3, 6 and 12 vs. baseline) outcome. In addition, full field visual evoked potentials, visual acuity, optical
coherence tomography as well as clinical relapses and measures of disability, cerebral MRI, and self-reported visual
quality of life were obtained for follow-up. The study was halted due to insufficient recruitment (n = 15), and
available results are reported.
Results: Per protocol analysis of the primary endpoint revealed a significantly larger reduction of mfVEP latency at
6 months compared to baseline with fingolimod treatment (n = 5; median decrease, 15.7 ms) than with IFN-β 1b
treatment (n = 4; median increase, 8.15 ms) (p < 0.001 for interaction). Statistical significance was maintained in the
secondary endpoint analysis. Descriptive results are reported for other endpoints.
Conclusion: Preliminary results of the MOVING trial argue in support of a beneficial effect of fingolimod on optic
nerve remyelination when compared to IFN-β treatment. Interpretation is limited by the small number of complete
observations, an unexpected deterioration of the control group and a difference in baseline mfVEP latencies. The
findings need to be confirmed in larger studies.
Trial registration: The trial was registered as EUDRA-CT 2011–004787-30 on October 26, 2012 and as NCT01647880
on July 24, 2012.
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Background
Relapsing-remitting multiple sclerosis (RRMS) is the
most common autoimmune disorder of the central ner-
vous system (CNS) and the leading cause of acquired
disability in young adults [1]. T-cell mediated auto-
immunity directed against myelin components of the
CNS is regarded as the central pathogenetic principle,
leading to multifocal demyelination, oligodendrocyte
apoptosis, and axonal dysfunction and transection [2].
Recovery from relapses involves remyelination of white
matter and optic nerve lesions after recruitment and dif-
ferentiation of oligodendrocyte precursors from the le-
sion perimeter [3, 4], but it is limited by axonal
degeneration and glial scarring which are observed even
at the earliest stages of the disease [5, 6]. With increas-
ing age and longer MS duration, a neurodegenerative
component may become predominant which progresses
independent of inflammatory activity [7, 8].
In recent years, an increasing range of immunomodu-
latory and immunosuppressive treatments has become
available which effectively reduce the frequency and se-
verity of inflammatory attacks and the accumulation of
relapse-related neurological deficits [9]. As an important
therapeutic gap however, current disease-modifying
therapies are not known to exert direct neuroprotective
effects or enhance remyelination [10].
Optic neuritis (ON) represents one of the most frequent
phenotypes of MS relapse and occurs as the first demye-
linating event in about one out of 3 MS patients [11, 12].
ON offers an elegant opportunity for studies of remyelina-
tion and neuroprotection in MS [13]. In particular, optic
nerve conduction can be followed up in a non-invasive,
standardized manner by measuring visual evoked poten-
tials (VEP): In the acute state, complete conduction block
may occur in severely demyelinated sections of surviving
axons, leading to reduction or loss of the VEP amplitude
[14]. Within the first month, reorganization of ion chan-
nels enables continuous, non-saltatory conduction in
demyelinated parts of the axons, and the degree of VEP
delay corresponds to the expanse of the lesion [14]. Over
the course of several months, remyelination re-establishes
saltatory conduction which is reflected in a gradual de-
crease of the VEP latency [15, 16].
High-dose pulsed corticosteroid treatment of ON may
shorten the duration of the acute attack but does not ne-
cessarily improve the long-term prognosis regarding vis-
ual function [17]. Intravenous methyl prednisolone,
usually given at a dose of 1 g on 5 consecutive days, is
frequently used for acute therapy, but dose-equivalent
oral treatment may be equally effective [18]. While at 6
months, overall recovery of high-contrast visual acuity is
usually good to excellent with 58% showing 20/20 vision
and just 6% 20/50 vision or worse [17], more subtle im-
pairment is found in many patients even after prolonged
periods of time [19–21]. This may include reduced
perception of color and contrast, or increased glare sen-
sitivity when driving or working at computer screens,
leading to a reduced quality of life [22]. VEP latencies re-
main prolonged even after full clinical recovery, indicat-
ing permanent loss or insufficient myelination of fast
conducting axons of the optic nerve. Spectral domain
optical coherence tomography (OCT) offers a reliable
non-invasive technique to investigate changes in the
thickness of retinal layers and their spatial distribution
[23, 24]. Using OCT, irreversible loss of axons and ret-
inal ganglion cell damage are detected as soon as four to
6 weeks after ON onset, being predictive of long-term
visual outcome [25, 26]. These findings suggest a limited
window of opportunity for effective neuroprotective
therapy in ON. Currently however, no recommendations
are available other than preventing further relapses by
initiating a disease-modifying therapy as soon as diag-
nostic criteria of multiple sclerosis or high-risk clinically
isolated syndrome (CIS) are met [27].
IFN-β 1b and IFN-β1a have been shown to decrease
number of clinical relapses, development of new focal
MRI lesions, and progression of disability in MS [28, 29].
Moreover, both forms of IFN-β significantly reduced the
rate of conversion to clinically definite MS in patients
with a first demyelinating event. Unlike other disease
modifying therapies, they are licensed and recommended
for use not only in RRMS, but also in CIS patients fulfill-
ing MRI criteria [27]. The ability of IFN-β to reduce pro-
gression of disability as well as the interpretation of
brain volume loss, especially in the first year of treat-
ment, continue to be matters of debate [30, 31]. IFN-β is
however not considered to have direct neuroprotective
effects or enhance remyelination in MS patients.
Fingolimod binds to sphingosin-1 phosphate receptors
(S1PR) [32], leading to aberrant phosphorylation, internal-
ization and degradation of S1PR [33]. Since S1PR are re-
quired for lymphocytes to exit lymphatic follicular
structures, fingolimod exerts immune modulation by se-
questering pathogenic T- and B-cells from the blood
stream [34]. Fingolimod is currently licensed for use in
RRMS but not CIS. While a first-line option in the US and
other countries, the European Medical Agency (EMA) label
reserves fingolimod for second-line therapy. In addition to
inducing S1PR degradation, S1PR-agonistic properties of
fingolimod may be relevant to its biological activity [35].
S1PR are also present on neurons, astrocytes and oligoden-
drocytes as well as resident and CNS-invading myeloid
cells, where they were shown to mediate neuroprotective
and pro-regenerative effects in preclinical studies [36–49].
Fingolimod readily crosses the blood brain barrier [50].
Compared to placebo or IFN-β 1a, fingolimod reduced
brain atrophy in MS patients which is thought to be driven
by neurodegeneration and synaptic loss [51–53]. Hence,
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use of fingolimod in the context of acute autoimmune de-
myelination could offer an advantage in terms of enhanced
remyelination, prevention of astrogliosis, and preservation
of axons, even as an early treatment. The present study
aimed to investigate protective and pro-regenerative effects
of fingolimod on the optic nerve of patients recovering
from acute unilateral optic neuritis.
Methods
Study design and participants
MOdification of VIsual outcomes in optic Neuritis using
Gilenya® (MOVING) was an investigator-driven, ran-
domized, rater-blind, active-controlled, parallel-group
study which recruited patients from two German MS
centers including one at the Charité university hospital
in Berlin as well as two academic teaching hospitals act-
ing conjointly as a study site in Potsdam. Eligible pa-
tients were 18 to 55 years of age with an acute first
manifestation of unilateral optic neuritis in the qualify-
ing eye with clinical onset within 30 days before screen-
ing. Additional requirements were an ipsilateral residual
vision (Snellen) of at least 0.1 and an abnormal full-field
VEP (ffVEP), elicited by 1° pattern reversal [54] with a
P100 latency of at least 115 ms or a delay of at least 15
ms compared to the fellow eye. Moreover, participants
had to fulfill diagnostic criteria of RRMS according to
the 2010 McDonald criteria [55] or of CIS with at least
two typical lesions on brain or spinal MRI. Patients were
excluded if they had an Expanded Disability Status Scale
(EDSS) [56] value greater than 6.0 or had suffered a de-
myelinating event other than ON within 30 days prior to
screening. Apart from treatment of the acute ON with
i.v. methylprednisolone, participants were required to
have received either no disease-modifying treatment in
the previous 3months or to have been on stable immu-
nomodulation using IFN-β or glatiramer acetate for at
least 6 months. Premenopausal women were excluded if
they were pregnant, breastfeeding or not using highly ef-
ficient contraception (Pearl index < 1). Patients were also
excluded if according to the current EU labels and
guidelines, treatment with IFN-β 1b or fingolimod, MRI
studies or use of gadolinium contrast agent were contra-
indicated or if there was comorbidity with potential im-
pact on the recovery from ON. A full list of inclusion
and exclusion criteria is available in the Additional file 1.
Randomisation and masking
Pre-specified randomization lists were generated for
each study site by the central study pharmacy, stratified
by residual vision (≤ 0.5 vs. > 0.5). Each allocation se-
quence used block permutation with a block size of 4.
After a screening phase of up to 2 weeks, eligible pa-
tients were randomly assigned on a 1:1 basis to receive
either a once-daily oral dose of 0.5 mg fingolimod or
subcutaneous injections of 250 μg IFN-β 1b every other
day for 6 months. All outcome-related data were col-
lected by a blinded rating physician and blinded techni-
cians. Participants and treating physicians were not
blinded regarding the treatment arm but instructed to
strictly maintain blinding of the raters. Patients who
completed the core study had the option to participate
in an additional follow-up visit after 12 months.
The intended sample size was calculated at 44 individ-
uals per group based on previously reported data on
mfVEP recovery in optic neuritis [15], an expected drop-
out rate of up to 20% and the assumption of a 30%
greater reduction of mfVEP latency after 6 months with
fingolimod treatment compared to IFN-β 1b.
Following initiation of the study, additional treatment
options for RRMS were licensed, including oral medica-
tions. In consequence, use of an injectable comparator
made the study unattractive to many patients. Recruit-
ment was significantly slowed and stopped prematurely
at the request of the funding source, Novartis Pharma.
Procedures
A treating neurologist at each site was responsible for
assessing eligibility, obtaining informed consent and
supervising study procedures in an unblinded manner,
including drug treatment, safety assessments, validation
of co-medications, and handling of adverse events. All
outcome-related data were collected in a blinded man-
ner by independent study personnel. The treatment
period started on the day of randomization (baseline
visit) by administering the first dose of study drug at the
study site. For patients randomized to fingolimod, 6 h
first dose cardiac monitoring was performed as man-
dated by the Summary of Product Characteristics, and
an additional safety visit was scheduled 2 months after
the last dose. In the IFN-β arm, participants were trained
in self-injecting the drug, and site personnel were avail-
able for troubleshooting between scheduled visits if
needed. Treatment adherence was verified by counting
returned medication at each visit. Three additional clin-
ical visits were performed after 1, 3 and 6months. A
synopsis of assessments and details of the protocols are
available in Supplementary Table S1. Ophthalmological
endpoints including multifocal and full-field VEP, high
and low contrast visual acuity, OCT, and self-reported
visual quality of life as well as the Multiple Sclerosis
Functional Composite Measure (MSFC) [57] and EDSS
were obtained at baseline and after 3 and 6months. MRI
was performed at baseline and after 6 months. Adverse
events reported by the participant or study personnel
were recorded throughout the study. Per protocol, pa-
tients with incident recurring ON in the qualifying eye
were excluded from the study. Other criteria for discon-
tinuation are available in the Additional file 1.
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Outcomes
The primary endpoint was the improvement of the
mfVEP latency from the qualifying eye at 6 months com-
pared to baseline, indicating the degree of remyelination
and restitution of axonal function of the optic nerve.
Measurements were performed in triplicate using a
RETIscan device (Roland Consult, Brandenburg,
Germany) and automatic postprocessing by mfPerimeter
software (Roland Consult). Secondary endpoints were
the improvement of the mfVEP latency from the qualify-
ing eye at 3 and 12 months compared to baseline. Fur-
ther exploratory endpoints included high and low
contrast visual acuity after 3 and 6months as deter-
mined by the number of correctly recognized letters on
100 and 2.5% contrast Sloan charts; retinal nerve fiber
layer thickness (RNFLT), total macular volume (TMV)
and ganglion cell and inner plexiform layer volume
(GCIPLV) after 3 and 6months as measured by spectral
domain OCT (Spectralis, Heidelberg Engineering, Hei-
delberg, Germany) [58], EDSS and MSFC at 3 and 6
months, as well as self-reported visual quality of life after
3 and 6months, using the composite score of the Na-
tional Eye Institute Visual Functioning Questionnaire
(NEI-VFQ39) [59]. On 3 Tesla brain MRI (TIM Trio,
Siemens, Erlangen, Germany), changes in the number
and volume of T2 hyperintense lesions at 6 months com-
pared to baseline and the number of contrast-enhancing
lesions on T1-weighted images after 6 months were de-
termined. For participants in the optional extension, all
outcomes were again evaluated 12 months after baseline.
For standardization, all studies were performed using a
single mfVEP device located in Potsdam as well as a sin-
gle OCT device and a single MR scanner located in
Berlin. Complete definitions and technical details of the
assessments are available in the Additional file 1. Study
oversight, on-site monitoring and source data verifica-
tion were performed independently by the clinical trial
facility at NeuroCure Clinical Research Center, Charité-
Universitätsmedizin, Berlin.
Statistical analysis
Results are reported as frequencies, or median with
minimum and maximum, depending on the scale of the
data (Table 1). Primary endpoint was the change in la-
tency of the multifocal visual evoked potential (mfVEP)
of the affected eye after 6 months of treatment com-
pared to mfVEP latency at baseline. The mfVEP was
modelled over time using non-parametric (rank-based)
ANOVA-like analyses for longitudinal data in factorial
settings, package ‘nparLD’, in R software [60] including
an interaction between time and treatment arm as indi-
cator for group differences in the mfVEP latency change.
As secondary analyses, this was repeated including also
data from 3 and 12months when available. OCT and
mfVEP results in the contralateral eye as well as the dif-
ference between ipsilateral and contralateral eyes have
also been assessed. Further important secondary end-
points analyzed in the same fashion were the cumulative
number of T2 lesions and the corresponding lesion vol-
ume measured at baseline and 6months as well as the
NEI-VFQ39 composite score. All other secondary end-
points are given with descriptive statistics only. Mann-
Whitney U tests were used to examine differences in
patient age at screening as well as time between symp-
tom onset and randomization between the two treat-
ment arms. To examine comparability of mfVEP and
ffVEP, Spearman’s correlation coefficient on ranks was
calculated for each time point. Statistical analyses were
performed using R software version 3.4.1. All tests were
2-sided, and statistical significance was determined at an
alpha level of 0.05. All p-values constitute exploratory
data analyses without adjustment for multiple compari-
sons. A re-estimate of the required sample size for the
primary endpoint was generated using nQuery Advisor
7.0 software (Statistical Solutions Ltd., Cork, Ireland),
based on the observed difference in mean mfVEP latency
change at month 6 vs. baseline and pooled standard
deviation.
Results
Participants were enrolled between June 2013 and April
2015. Of 15 screened patients, 13 were eligible for inclu-
sion (Fig. 1). One patient withdrew consent, and one
patient suffered a relapse of optic neuritis while in the
screening period. Of the eligible patients, 6 were random-
ized to fingolimod and 7 were randomized to INF-β 1b.
Median delay between onset of symptoms and
randomization was 27 days in the fingolimod arm (range,
22–37 days) and 33 days in the interferon arm (range, 16–
49 days; p = 0.285; Mann-Whitney U test). All patients re-
ceived their assigned treatment. A total of 9 participants
completed the 6months treatment period, and 6 of these
were available for extended follow-up at month 12. Two
participants in the fingolimod arm sustained relapses. One
of these had recurrent ON in the qualifying eye, leading to
exclusion from the study. In the interferon arm, two par-
ticipants relapsed. Each had recurrent ON (ipsilateral, n =
2; bilateral n = 1), also leading to exclusion.
Descriptive statistics including ipsilateral OCT and
VEP are given in Table 1. OCT and mfVEP results in
the contralateral eye as well as the difference between
ipsilateral and contralateral eyes can be found in the
Additional file 1 (Supplementary Tables S2 and S3).
Baseline characteristics revealed a higher frequency of
CIS in the interferon group (6 out of 7) compared to the
fingolimod group (2 out of 6). Furthermore, patients
with fingolimod treatment had lower MSFC scores and
visual acuity as well as longer median mfVEP and ffVEP
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Table 1 Descriptive statistics
Fingolimod Missing IFN-β 1b Missing
Male / Female [n] 3 / 3 – 2 / 5 –
CIS / RRMS [n] 2 / 4 – 6 / 1 –
Age [years] 41 (28; 51) – 51 (24; 54) –
EDSS Baseline 1.5 (0; 3) – 1.5 (1; 2) –
3 months 1.5 (0; 3) 1 1 (1; 1) 4
6 months 1.5 (0; 3) 1 1.25 (1; 1.5) 3
MSFC Baseline −0.10 (−0.87; 0.21) – 0.18 (−1.27; 1) –
3 months −0.07 (− 0.30; 0.19) 1 0.47 (− 1.39; 0.87) 2
6 months 0.09 (− 0.27; 0.59) 2 0.08 (− 1.36; 0.64) 1
mfVEP Latency [ms] Baseline 112.65 (107.1; 120.3) – 95.8 (90.7; 108.1) –
3 months 105.05 (92.8; 120.3) 2 120.3 (106; 120.3) 4
6 months 94.8 (92.8; 113.2) 1 109.1 (94.8; 120.3) 3
Δ = 6months - Baseline −15.7 (−19.3; 6.1) 1 8.15 (3.1; 24.5) 3
ffVEP P100 [ms] Baseline 129.7 (119.2; 148.5) – 122.1 (113.6; 145) –
3 months 125 (108; 144.4) 3 113.18 (112.15; 114.2) 5
6 months 119.2 (93.9; 143.2) 1 109.8 (97.15; 110.4) 4
RNFLT [μm] Baseline 94 (79; 116) 1 96 (84; 124) 1
3 months 88.5 (82; 112) 2 82 (77; 92) 3
6 months 83 (76; 110) 1 80.5 (75; 88) 3
Δ = 6months - Baseline −9 (−13; −6) 2 −6 (− 14; − 3) 4
GCIPLV [mm3] Baseline 1.75 (1.46; 2.23) 1 1.7 (1.44; 2.13) 1
3 months 1.79 (1.67; 2.14) 2 1.65 (1.42; 1.89) 3
6 months 1.72 (1.45; 2.14) 1 1.68 (1.38; 1.89) 3
Δ = 6months - Baseline −0.065 (−0.09; −0.01) 2 −0.03 (−0.16; 0.01) 4
TMV [mm3] Baseline 8.33 (8.14; 9.34) 1 8.36 (6.58; 9) 1
3 months 8.5 (8.12; 9.31) 2 8.52 (7.58; 8.71) 3
6 months 8.25 (8.03; 9.06) 1 8.46 (7.5; 8.7) 3
Δ = 6months - Baseline −0.28 (−0.3; −0.09) 2 −0.12 (− 0.41; − 0.11) 4
Sloan 100% Baseline 32 (29; 39) 1 37 (35; 39) 5
[n letters] 3 months 35 (35; 39) 3 40 (40; 40) 6
6 months 40 (35; 44) 1 39 (29; 40) 4
Sloan 2.5% Baseline 0 (0; 9) 1 2.5 (0; 5) 5
[n letters] 3 months 4 (3; 5) 3 2 (2; 2) 6
6 months 6 (0; 15) 1 1 (0; 13) 4
NEI-VFQ 39 Baseline 87.46 (76.63; 92.08) 3 88.71 (72.5; 94.28) 3
Composite Score 3 months 92.84 (81.40; 94.33) 3 87.52 (75; 97.05) 3
6 months 90.15 (78.30; 98.58) 3 74.60 (71.44; 84.85) 3
T2 Lesion Count Baseline 34 (21; 64) – 33 (15; 56) –
[n] 6 months 34 (23; 37) 1 31.5 (14; 54) 3
Δ = 6months - Baseline 2 (0; 2) 1 −1 (−2; 1) 3
T2 Lesion Volume Baseline 3.57 (1.88; 5.5) – 2.95 (0.91; 11.89) –
[ml] 6 months 4.56 (2.11; 5.89) 1 2.77 (1.24; 12.56) 3
Δ = 6months - Baseline 0.362 (0.11; 0.47) 1 0.31 (0.09; 0.67) 3
T2 New Lesion Count [n] 6 months - Baseline 2 (0; 3) 1 1.5 (1; 4) 3
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latencies at baseline compared to the IFN-ß 1b arm. Age
at screening was more widely distributed in the inter-
feron group (24–54 years; median, 51 years; mean, 42.0
years) than in the fingolimod group (28–51 years; me-
dian, 41 years; mean, 39.7 years). No significant differ-
ence in age was detected between groups (p = 0.617;
Mann-Whitney U test).
No eyes had loss of the mfVEP signal at screening or
during follow up. Efficacy analysis of the primary end-
point including only complete measurements at baseline
and 6months follow-up showed that the latency of
mfVEP from the affected eye increased compared to
baseline in the IFN-β arm while it decreased over time
in the fingolimod arm. Nonparametric modelling re-
vealed a significant difference in change over time
between the two study arms (interaction arm*time: p =
0.001, Fig. 2). Main effects of time and treatment arm
were not statistically significant. Relative treatment ef-
fects with 95% confidence intervals are given in Table 2.
Secondary analyses including also 3 months and 12
months data showed similar results, although there were
only 3 complete cases per treatment arm (Table 2 and
Supplementary Figure 1). Intention-to-treat evaluation
of these endpoints is depicted in Supplementary Figure
2. In the contralateral eye, there was a similar median in-
crease of the mfVEP latency in the interferon group and
a smaller median decrease in the fingolimod arm, but
the difference in change over time was not statistically
significant (interaction arm*time: p = 0.410, Supplemen-
tary Figure S3 and Supplementary Table S2). Similar ob-
servations were made regarding the relative delay of the
mfVEP latency from the affected eye compared to the
contralateral eye (interaction arm*time: p = 0.269, Sup-
plementary Figure S4 and Supplementary Table S2).
Table 1 Descriptive statistics (Continued)
Fingolimod Missing IFN-β 1b Missing
T2 New Lesion Volume [ml] 6 months - Baseline 0.11 (0.00; 1.234) 1 0.226 (0.119; 1.085) 3
T2 Lesions with Increased Volume [n] 6 months - Baseline 12 (4; 18) 1 12.5 (4; 18) 3
T1 Gd-enhancing Baseline 0 (0; 3) 1 0 (0; 6) 2
Lesions [n] 6 months 0 (0; 1) 1 0 (0; 2) 3
Δ = 6months - Baseline 0 (0; 1) 2 0 (0; 0) 4
Results are reported as frequencies, or median and range. RFNLT, GCIPLV, TMV, mfVEP and ffVEP are reported for the affected eye
Fig. 1 Patient disposition
Albert et al. BMC Neurology           (2020) 20:75 Page 6 of 12
The cumulative number of T2 lesions and the corre-
sponding lesion volumes did not significantly differ in
change over time (baseline, 6 months) between treatment
arms (Table 2). Low values of RNFLT, GCIPLV and TMV
were present in the affected eye in most participants at
baseline, with further deterioration over time (Table 1).
Only minor intraindividual changes of contralateral TMV,
RNFLT and GCIPLV at 6months vs. baseline were ob-
served in both treatment arms (Supplementary Table S2).
Relative to the contralateral eye, both treatment arms dis-
played a similar median loss of RNFLT and GCIPLV,
while TMV loss appeared to be nominally smaller in the
fingolimod arm (Supplementary Table S3).
An apparent trend for improved visual quality of life with
fingolimod treatment did not meet statistical significance
(interaction treatment arm*time: p = 0.122; Supplementary
Figure S5). No clear correlation was discernible between ip-
silateral mfVEP and ffVEP latencies at any time point (base-
line: r = 0.230 (n = 13); 3months: r = 0.447 (n = 5); 6
months: r= − 0.241 (n = 8); 12months: r = 0.414 (n = 7)).
The primary outcome was used for a re-calculation of
the required sample size. The mean change in mfVEP la-
tency over 6 months was − 11.5 ms in the fingolimod
arm and + 11.0 ms in the interferon arm, corresponding
to a difference of 22.5 ms between groups with a pooled
standard deviation of 10.2 ms. The nominal effect size
Fig. 2 Treatment effect on change in multifocal VEP latency from the qualifying eye. Preliminary analysis of the primary endpoint, change in
mfVEP latency from the qualifying eye. Black, fingolimod. Red, IFN-β 1b. a Individual follow-up of the mfVEP latency from the qualifying eye. b
Results of the non-parametric longitudinal data analysis using the R package ‘nparLD’. Relative treatment effects with 95%-confidence intervals for
complete cases only (fingolimod, N = 5; IFN-β 1b, N = 4; p- value for interaction, 0.001)
Table 2 Statistical analysis of endpoints
Time Relative Effect, Fingolimod N Relative Effect, IFN-β 1b N P-value
Treatment
Arm
P-value
Time
P-value
Interaction
mfVEP Latency Baseline 0.6889 (0.4692; 0.8060) 5 0.2917 (0.2029; 0.4268) 4 0.630 0.905 0.001
6 months 0.3778 (0.2134; 0.6298) 5 0.6250 (0.3622; 0.8020) 4
T2 Lesion Count Baseline 0.4500 (0.2635; 0.6684) 5 0.5139 (0.2871; 0.7316) 4 0.935 0.239 0.164
6 months 0.5333 (0.3257; 0.7209) 5 0.5069 (0.2423; 0.7653) 4
T2 Lesion Volume Baseline 0.5056 (0.3180; 0.6902) 5 0.4167 (0.2184; 0.6738) 4 0.696 < 0.001 0.876
6 months 0.5722 (0.3642; 0.7400) 5 0.4861 (0.2654; 0.7161) 4
mfVEP Latency Baseline 0.6736 (0.3338; 0.8699) 3 0.2569 (0.1119; 0.5675) 3 0.400 0.773 0.004
3 months 0.2778 (0.1084; 0.6384) 3 0.7292 (0.5522; 0.8409) 3
6 months 0.4514 (0.1781; 0.7694) 3 0.6528 (0.2843; 0.8734) 3
12 months 0.3125 (0.1371; 0.6153) 3 0.6458 (0.4587; 0.7875) 3
Statistical evaluation of the primary endpoint, mfVEP at 6 months compared to baseline, and of secondary endpoints (T2 lesion count and volume on brain MRI at
6 months vs. baseline; mfVEP latency at 3, 6 and 12 months vs. baseline). Estimation of relative effect size and unadjusted p values using non-parametric ANOVA-
type statistics. Values in parentheses represent 95% confidence intervals. Only complete cases are included
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(Cohen’s d) of treatment with fingolimod vs. IFN-β 1b
was calculated at 2.2. Considering the small number of
complete observations, even a more conservative ap-
proach using Cohen’s d = 1.0 predicts that a sample size
of 20 per group would be sufficient to determine a dif-
ferential effect of the two treatments with a 0,05 two-
sided significance level at 80% power, using a Wilcoxon
(Mann-Whitney) rank-sum test.
No new safety signals were detected in either treat-
ment arm. In total, there were 10 adverse events (AE) in
4 participants receiving fingolimod and 10 AE in 4 pa-
tients in the interferon arm. A causal relationship was
considered possible to fingolimod for 2 AE and to IFN-β
1b for one AE, while causality could not be determined
for two AE experienced by one IFN-β 1b-treated patient.
A full list of AE is available in Supplementary Table S4.
All AE were of mild or moderate intensity. One patient
in the fingolimod arm sustained a serious AE (SAE) re-
quiring hospitalization which was deemed unrelated to
the drug. None of the AE or SAE resulted in death, dis-
continuation or change of treatment.
Discussion
The MOVING trial investigated whether recovery from
unilateral optic neuritis in MS or CIS patients is im-
proved by the S1PR modulator fingolimod compared to
conventional treatment with IFN-β 1b. For the primary
endpoint, a decrease of the ipsilateral mfVEP latency
was observed after 6 months of fingolimod treatment,
while an increase was observed with IFN-β 1b, and stat-
istical significance was met for the effect of treatment
over time. Interpretation of these results is limited since
pre-planned sample sizes were not reached.
The statistical model revealed no significant main ef-
fect of the study arm on the primary outcome, arguing
against a chance effect of randomization. Rather, the ef-
fect of treatment over time was significant both in the
primary analysis and when including the secondary end-
points, i.e. mfVEP latencies at 3 and 12months. Multi-
variable analyses were not undertaken due to the small
number of observations. It should be noted that the
most severe forms of ON are not represented in this
study, since patients with residual vision of less than 0.1
or complete loss of VEP signal were not eligible.
The median improvement of mfVEP latencies in the fin-
golimod group is at the upper limit of what has previously
been reported with this method in a cohort selected by
good visual recovery [15]. A trend towards an increase of
mfVEP latencies in the IFN-β group was not expected.
However, preclinical findings do not argue against nega-
tive effects of IFN-β on remyelination. IFN-β inhibited the
differentiation of oligodendrocyte precursors in mixed
glial cultures [61]. In cuprizone-induced demyelination,
IFNβ-deficient mice showed accelerated remyelination of
the corpus callosum [62], and long-term IFN-β treatment
of mice aggravated viral-induced demyelination [63]. Con-
versely, no effect of IFN-β on ffVEP latency recovery or
RNFL thinning was reported in a 16-week open label
study of patients with clinically isolated optic neuritis [64].
Looking at possible confounders, a larger proportion
of participants with established MS vs. CIS as well as
higher numbers of T2 lesions were randomized to the
fingolimod arm, suggesting a longer duration of demye-
linating disease in this group, which could negatively
affect the capacity for remyelination [65]. Also, a more
pronounced delay of ipsilateral mfVEP and ffVEP laten-
cies and poorer performance on 100 and 2.5% contrast
Sloan charts seemed to be present at baseline in the fin-
golimod arm, which could differentially affect change
rates but also suggests a more severe manifestation and
poorer a priori prognosis of ON in this group.
Relapses including recurrent optic neuritis occurred
more frequently in the interferon arm compared to fin-
golimod. The finding is most likely explained by a differ-
ential treatment effect on the prevention of relapses [52,
66]. However, except for one relapse in the fingolimod
arm, all were events of recurrent ON and led to exclu-
sion from the study. Patients who contributed to the
analysis had similar low frequencies of new or enlarging
T2 lesions as well as Gd-enhancing lesions at 6 months.
It is therefore unlikely that the difference in mfVEP la-
tency change between groups is mediated by clinical or
subclinical disease activity.
In the pivotal trials in RRMS, fingolimod significantly
reduced brain atrophy and disability progression over 12
to 24months when compared to placebo or IFN-β treat-
ment [51, 52]. However, it is not clear to what degree
these findings indicate direct neuroprotection by fingoli-
mod or reflect downstream effects of reduced inflamma-
tory activity: In a pooled analysis of the TRANSFORMS
trial, the presence of gadolinium enhancing T1 lesions at
baseline was the strongest predictor of brain atrophy [66].
On the other hand, a post hoc analysis of the FREEDOMS
trial indicated independent effects of the reduction of re-
lapses and of decreased brain volume loss on disability
progression [67]. In primary progressive MS, fingolimod
had no significant effect on disability progression or brain
atrophy [68]. Difficulties in studying neuroprotection by
fingolimod in clinical trials, even using advanced MRI
techniques or cognition as a surrogate endpoint, have
been pointed out in a recent review [69]. Similarly, an in-
crease in macular volume on OCT has been reported in
fingolimod-treated patients [70], which however are likely
to reflect off-target effects rather than neuroprotection
[71]. In view of this context, the results of the MOVING
trial may represent the first indication of a superior effect
of fingolimod on remyelination and preservation of axonal
function compared to interferon treatment.
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In both treatment arms, conventional ffVEP demon-
strated a trend towards reduction of P100 latencies after
6 months, consistent with earlier studies [16, 72–74].
However, ffVEP and mfVEP were only weakly correlated
at baseline and after 3 and 6months of follow-up. Unlike
ffVEP, which largely represents macular vision, mfVEP
examines nerve conduction from the entire visual field
including peripheral lesions. Previous studies have
pointed out a superior sensitivity and specificity of
mfVEP compared to ffVEP in ON [75]. Interestingly, the
differential effect of the two treatments in MOVING ap-
peared to be in parallel with changes of the self-reported
visual quality of life.
As further parameters of integrity of the optic system,
RNFLT, GCIPLV and TMV were followed up in the
qualifying eye. All parameters showed considerable vari-
ance at baseline. In both treatment arms, a large propor-
tion of participants had reduced RNFLT even before
randomization and displayed a further decrease after 6
months. No obvious differential effect of the two treat-
ments was detectable, as was the case for TMV and
GCIPLV or when using the contralateral eye as a refer-
ence. Post-inflammatory retinal atrophy is an expected
outcome after ON [76]. GCIPLV loss may start as early
as 8 days after ON onset [77], and RNFL thinning has
been reported as early as after 1 month, being predictive
of progressive atrophy at month 6 [78]. Increased
RNFLT due to edematous swelling, which may be
present in the hyperacute state [79], was not observed.
These findings may indicate that a window of up to 6
weeks between clinical onset and randomization in the
MOVING trial may be too generous since a relevant de-
gree of neuronal loss may already have occurred [26],
thus limiting the impact of neuroprotective therapies. In-
deed, other studies reporting protective effects of
erythropoietin [80] or phenytoin [81] randomized pa-
tients within 10 and 14 days after ON onset, respectively.
Recovery from ON has also been studied in the recent
multicenter RENEW trial of opicinumab [82]. Opicinu-
mab, a monoclonal antibody directed against LINGO-1,
was hypothesized to enhance remyelination by directly
promoting proliferation and differentiation of oligo-
dendrocyte precursors. Notably, LINGO-1 blockade has
no detectable immune modulatory effects [83]. While no
significantly different effect of anti-LINGO-1 (n = 41) vs.
placebo treatment (n = 41) on ffVEP latency decrease
was observed in the intention-to-treat analysis, per-
protocol analysis of 69 patients indicated potential effi-
cacy of this approach after 32 weeks. No effect on
GCIPLV decrease was detected, which could again be re-
lated to a mean delay of 24 days between ON onset and
start of treatment. Based on this discrepancy the authors
argued that therapeutic windows may be longer for
remyelination compared to neuroprotection [82].
Additional possible confounders which were not
accounted for in the MOVING protocol have since been
described. MOVING had no specific rules in place to limit
the delay between ON onset and initiation of corticoster-
oid therapy, which may affect visual recovery [84, 85].
Moreover, we did not evaluate focal lesions in the poster-
ior visual pathways, which were recently described to be
associated with RNFLT loss and delayed VEP [86, 87].
The MOVING trial was hampered by slow recruit-
ment and incomplete follow-up. An effort to enlist add-
itional sites was made but remained unsuccessful. For
ethical reasons, a confirmed diagnosis of MS or CIS with
at least 2 T2 hyperintense lesions on MRI was required
for inclusion. As a major obstacle, eligible patients often
viewed the use of an injectable interferon in the com-
parator arm as unattractive once dimethyl fumarate, teri-
flunomide and alemtuzumab had become available as
alternative treatments for relapsing MS. This is reflected
in a high proportion of CIS patients among the partici-
pants. Given the difficult recruitment, protocol devia-
tions were tolerated as long as minimum treatment
requirements were met and an unbiased evaluation of
the primary outcome was expected.
Conclusions
To summarize, available data from the prematurely
stopped MOVING trial lends tentative support to the
hypothesis that treatment with fingolimod may be asso-
ciated with a better recovery from unilateral optic neur-
itis compared to treatment with IFN-β 1b. If
corroborated, the findings argue in favor of the hypoth-
esis that fingolimod may promote remyelination in auto-
immune demyelinating disease. The observed treatment
effect however should be interpreted with caution, as it
may be attributable to a positive effect of fingolimod, a
detrimental effect of interferon beta, both, or even an
artifact due to the low sample size and incomplete fol-
low up.
Current and previous experience underlines the role of
ON as a particularly suited model to study remyelination
in autoimmune CNS demyelinating disease, including
pharmacological effects [13]. Use of mfVEP rather than
ffVEP as a primary endpoint may offer advantages in
terms of sensitivity and required group sizes. MOVING
may be viewed as an encouragement for a repeat clinical
trial. From our current experience, we recommend a
multicenter study with a significantly shorter window for
inclusion after onset of ON. An oral comparator should
be used to facilitate recruitment and support a true
double-blind design. To reduce baseline heterogeneity,
mfVEP rather than ffVEP should be used as an inclusion
criterion. A low sample size of 20 per arm may be suffi-
cient using ipsilateral mfVEP latency decrease over 6
months as the primary outcome.
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